The guidance cut signals material near-term headwinds in the Ultramist capital equipment segment. Traders should watch for Q2 actual results and any updates on CMS reimbursement trends. The strong applicator consumable business provides a partial offset but does not eliminate the revenue shortfall.
Price Chart
Executive Summary
SANUWAVE Health lowered its Q2 2026 revenue guidance to $8.5-$9.5 million, citing CMS reimbursement clawbacks causing wound care practice closures and a secondary market for used Ultramist systems that is cannibalizing new system sales. While applicator consumable volumes are on pace for a record quarter, the capital equipment business faces significant near-term headwinds.
Key Facts
- Q2 2026 revenue guidance lowered to $8.5M-$9.5M, below prior guidance provided on May 13, 2026
- Widespread CMS reimbursement clawbacks for skin substitutes/allografts are driving wound care practice closures and liquidations
- Used Ultramist systems entering the secondary market are cannibalizing new system sales
- Applicator (consumable) unit volumes are on pace for a record quarterly shipment in Q2
Financial Impact
Q2 2026 revenue expected $8.5M-$9.5M, below prior guidance; CMS reimbursement disruption impacting capital equipment sales
Risk Factors
- Further wound care practice closures reducing the addressable market
- Growth of secondary market for used Ultramist systems depressing new system demand
- Inability to sustain applicator growth if system placements decline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-043419 |
| Exhibit: ex-991snwvpressreleasex616.htm | 0001628280-26-043419 |
| Document: 0001628280-26-043419-index-headers.html | 0001628280-26-043419 |
| Document: 0001628280-26-043419-index.html | 0001628280-26-043419 |
| Document: 0001628280-26-043419.txt | 0001628280-26-043419 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $4.65 $4.70 | ▼ −1.08% | ▲ +0.13% | $5.13 (−10.22%) |
Aug 6, 2026 11w ago | 8-K | $5.88 $4.74 | ▲ +19.39% | ▲ +19.79% | $5.13 (+12.84%) |
Aug 6, 2026 11w ago | Press Release | $5.88 $4.74 | ▲ +19.39% | ▲ +19.79% | $5.13 (+12.84%) |
Jul 30, 2026 12w ago | Press Release | $6.17 $5.88 | ▼ −4.70% | ▼ −8.21% | $5.13 (−16.94%) |
Jun 16, 2026 19w ago | 8-K | $8.51 $8.20 | ▲ +3.64% | ▲ +1.41% | $5.13 (+39.78%) |
Jun 16, 2026 19w ago | Press Release | $8.51 $8.20 | ▲ +3.64% | ▲ +1.41% | $5.13 (+39.78%) |
Jun 11, 2026 19w ago | Institutional Cluster | $14.69 $9.09 | ▼ −38.12% | ▼ −38.55% | $5.13 (−65.11%) |
May 12, 2026 23w ago | Press Release | $18.94 $16.69 | ▼ −11.88% | ▼ −10.72% | $5.13 (−72.94%) |
May 6, 2026 24w ago | Press Release | $16.65 $18.94 | ▲ +13.75% | ▲ +12.25% | $5.13 (−69.22%) |
Apr 16, 2026 27w ago | 8-K | $20.61 $18.70 | ▼ −9.27% | ▼ −9.82% | $5.13 (−75.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers